ABT-494

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
BackgroundAnti-cytokine therapies such as adalimumab, tocilizumab, and the small molecule JAK inhibitor tofacitinib have proven… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2016
2016
OBJECTIVE To evaluate the efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in patients with moderate-to-severe… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2016
2016
OBJECTIVE To compare the efficacy and safety of ABT-494, a novel selective JAK-1 inhibitor, with placebo in patients with… (More)
  • figure 1
  • table 1
  • figure 2
  • table 3
  • figure 3
Is this relevant?
2016
2016
BackgroundABT-494 is a potent and selective Janus kinase (JAK) 1 inhibitor being developed for the treatment of several… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Review
2016
Review
2016
Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by synovial inflammation and joint destruction… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Review
2016
Review
2016
Background ABT-494 is a novel selective JAK1 inhibitor. Objectives The safety, efficacy, and dose response of ABT-494 were… (More)
Is this relevant?
Review
2016
Review
2016
Background ABT-494 is a novel selective JAK1 inhibitor. Objectives The safety and efficacy of ABT-494 was characterized vs… (More)
Is this relevant?
2015
2015
Background Janus activated kinase (Jak) inhibition has shown clinical benefits in treatment of rheumatoid arthritis (RA). However… (More)
Is this relevant?
2014
2014
Background Anti-cytokine therapies have become the mainstay of treatment for rheumatoid arthritis (RA) disease symptoms and can… (More)
Is this relevant?